Corporate Collaboration Aiming for a Society That Does Not Fear Aging: 'Epiclock® Co-creation Project' Phase 3 Activity Starts

Rhelixa, Inc. launched Phase 3 of its 'Epiclock® Co-creation Project' on April 1, 2026. This corporate collaboration project aims to realize a society that does not fear aging by visualizing and controlling the aging process, based on 'epigenetic clock' technology, which evaluates biological age. In Phase 3, the company welcomes new partner companies and will accelerate efforts based on the following activity policies: building anti-aging evidence, developing solutions, and fostering the social adoption of the concept of 'biological age.'

Activity Policies

This project operates under three activity policies:

(1) Building Evidence Construct new anti-aging evidence through the exploration of aging inhibitory factors and verification of intervention/behavioral change effects.

(2) Developing Solutions Aim to create new, effective, and essential anti-aging solutions by transcending corporate boundaries.

(3) Social Penetration Foster social acceptance of biological age through active information dissemination, while aiming to create and develop the anti-aging market.

Co-creation Partner Companies

The companies listed below have newly joined the project through the Phase 3 open call. Together with companies continuing from Phase 1 and 2, we will promote the creation and development of the anti-aging market through R&D, business development, and information dissemination.

Information regarding the Epiclock® Co-creation Project will be released on the following web page: https://epiclock.jp/#news

Related Press Releases

- Corporate Collaboration Aiming for a Society That Does Not Fear Aging: 'Epiclock® Co-creation Project' Phase 1 Activity Starts (https://www.rhelixa.com/eccpj-2024/) - Corporate Collaboration Aiming for a Society That Does Not Fear Aging: 'Epiclock® Co-creation Project' Phase 2 Activity Starts (https://www.rhelixa.com/eccpj-2025/)

[Contact for Inquiries regarding this release]

Management Planning Office, Rhelixa, Inc. Email: [email protected]

[About Rhelixa, Inc.]

Rhelixa, Inc. utilizes techniques cultivated through cutting-edge genome and epigenome analysis to conduct basic research, develop products and solutions, and provide commissioned services in the fields of biology, medicine, and pharmacy. By combining epigenome data obtained from next-generation sequencers with genome, transcriptome, and metagenome data, the company performs integrated data analysis to predict detailed cellular control mechanisms and discover highly accurate markers. Additionally, it provides an environment where anyone can perform statistical analysis and create figures necessary in all research and development settings without requiring foundational knowledge.